Cardiometabolic therapy and mortality in very old patients with diabetes hospitalized due to COVID-19

22Citations
Citations of this article
73Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients =80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. Method: We conducted a nationwide, multicenter, observational study in patients =80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Results: Of the 2 763 patients =80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confdence interval [CI]: 0.309-0.815, p =.005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p =.003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p =.020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. Conclusions: We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.

Cite

CITATION STYLE

APA

Ramos-Rincón, J. M., Pérez-Belmonte, L. M., Carrasco-Sánchez, F. J., Jansen-Chaparro, S., De-Sousa-Baena, M., Bueno-Fonseca, J., … Gómez-Huelgas, R. (2021). Cardiometabolic therapy and mortality in very old patients with diabetes hospitalized due to COVID-19. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 76(8), E102–E109. https://doi.org/10.1093/gerona/glab124

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free